Nivolumab + Relatlimab
Opdualag®
Nivolumab: Inhibits interaction with PD-L1 and PD-L2 ligands on cancer cells
Relatlimab: Binds to LAG-3 receptor and thereby cancelling the inhibition of the immune response mediated by LAG-3 by blocking its interaction with ligands.
12/2022
Non-resectable or metastatic melanoma with PD-L1 expression < 1%
Differential blood count, biochemical panel (sodium, potassium, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, ASAT, ALAT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose, cortisol, TSH, fT4, high-sensitivity troponin T, troponin I, NT-pro BNP, S-100, pregnancy test, viral serologies if necessary (hepatitis B/C, HIV, CMV, EBV) ECG, echocardiography (if cardiovascular risk is present)
Before each administration: differential blood count, biochemical panel (sodium, potassium, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, ASAT, ALAT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose; every 2 months: TSH, fT4
(If necessary, initial weekly monitoring of the differential blood count and biochemical panel)
Administered every 4 weeks as an intravenous infusion over 30 minutes
Treatment should be continued as long as a clinical benefit is observed or until the treatment is no longer tolerated by the patient.
Refer to the relevant medical literature, guidelines, and clinical studies.
- Women: negative pregnancy test, dual contraception up to 5 months after the last infusion
- No live vaccines 30 days before the start of and during therapy